Nervonik
Medical technology company developing miniaturized peripheral neuromodulation implants and supporting wearable wireless power and digital-control systems for treatment of chronic neuropathic pain. Devices are described as research- and veterinary-use currently while the company pursues human regulatory approvals and has conducted early human feasibility studies.
Industries
Nr. of Employees
small (1-50)
Products
Research-use peripheral neuromodulation implant system
Miniaturized implantable pulse generator and leads designed to stimulate peripheral nerves, powered wirelessly by an external wearable power device and controllable via a mobile app. Offered for research and veterinary use while human regulatory approvals are pending.
Research-use peripheral neuromodulation implant system
Miniaturized implantable pulse generator and leads designed to stimulate peripheral nerves, powered wirelessly by an external wearable power device and controllable via a mobile app. Offered for research and veterinary use while human regulatory approvals are pending.
Services
Design and execution support for early-stage clinical feasibility studies of peripheral nerve stimulation devices at partner clinical sites.
Design and execution support for early-stage clinical feasibility studies of peripheral nerve stimulation devices at partner clinical sites.
Expertise Areas
- Peripheral neuromodulation
- Neurotechnology device engineering
- Wireless power transfer for implants
- Digital health and device telemetry
Key Technologies
- Peripheral nerve stimulation (PNS)
- Miniaturized implantable pulse generators
- Wearable wireless power transfer (WPT)
- Closed-loop sensing and adaptive stimulation
News & Updates
Announcement of successful completion of a first-in-human feasibility study using a peripheral nerve stimulation device; study conducted at Punta Pacifica Hospital (Panama), with leads implanted using fluoroscopy and ultrasound and implants powered wirelessly and programmed via app. Results to be compiled and presented in early 2025.
Announcement that regulatory approval was obtained to initiate a first-in-human feasibility study of a peripheral nerve stimulation technology focused on chronic pain of peripheral nerve origin; study enrollment was anticipated to begin in Q3 2024.
Announcement of successful completion of a first-in-human feasibility study using a peripheral nerve stimulation device; study conducted at Punta Pacifica Hospital (Panama), with leads implanted using fluoroscopy and ultrasound and implants powered wirelessly and programmed via app. Results to be compiled and presented in early 2025.
Announcement that regulatory approval was obtained to initiate a first-in-human feasibility study of a peripheral nerve stimulation technology focused on chronic pain of peripheral nerve origin; study enrollment was anticipated to begin in Q3 2024.